{
  "metadata": {
    "dataset_name": "Clinical Trials API Stub",
    "version": "1.0",
    "generated_date": "2025-12-07",
    "description": "Simulated dataset of ongoing global clinical trials for EY Techathon 6.0 project.",
    "source_style": ["ClinicalTrials.gov", "EMA Trial Registry", "WHO ICTRP"]
  },

  "trials": [
    {
      "trial_id": "CT-2025-001",
      "title": "A Phase III Study of Semaglutide for Weight Management in Non-Diabetic Obese Patients",
      "molecule": "Semaglutide",
      "therapy_area": "Metabolic / Obesity",
      "phase": "Phase 3",
      "status": "Recruiting",
      "start_date": "2024-04-01",
      "estimated_completion_date": "2027-09-30",
      "study_type": "Interventional",
      "intervention_type": "Drug - GLP-1 Analog",
      "sample_size": 3800,
      "countries": ["USA", "Canada", "UK", "Germany", "India"],
      "sponsor": {
        "name": "Novo Nordisk",
        "type": "Industry"
      },
      "collaborators": ["University of Toronto", "Cleveland Clinic"],
      "indication_specifics": {
        "subtype": "Non-diabetic obesity (BMI > 35)",
        "primary_endpoint": "Percent weight reduction at week 60",
        "secondary_endpoints": ["Waist circumference", "Cardiometabolic markers"]
      },
      "competitive_density_score_10": 9,
      "risk_of_late_stage_competitor": "High",
      "opportunity_relevance_score_10": 7,
      "notes": "High global competition; strong relevance for metabolic expansion insights."
    },

    {
      "trial_id": "CT-2025-002",
      "title": "Osimertinib in Combination With Novel KRAS Inhibitor for EGFR-Mutant NSCLC",
      "molecule": "Osimertinib",
      "therapy_area": "Oncology (EGFR / NSCLC)",
      "phase": "Phase 1/2",
      "status": "Active, Not Recruiting",
      "start_date": "2023-06-01",
      "estimated_completion_date": "2026-12-15",
      "study_type": "Interventional",
      "sample_size": 240,
      "countries": ["USA", "Japan", "South Korea"],
      "sponsor": {
        "name": "AstraZeneca",
        "type": "Industry"
      },
      "collaborators": ["Dana-Farber Cancer Institute"],
      "indication_specifics": {
        "mutation": "EGFR T790M",
        "primary_endpoint": "Dose-limiting toxicity (DLT)",
        "secondary_endpoints": ["Overall survival", "PFS", "ORR"]
      },
      "competitive_density_score_10": 7,
      "risk_of_late_stage_competitor": "Medium",
      "opportunity_relevance_score_10": 9,
      "notes": "Combination trial insights help define unmet needs and competitive saturation."
    },

    {
      "trial_id": "CT-2025-003",
      "title": "Long-Acting Cabotegravir for HIV Prevention in High-Risk Populations",
      "molecule": "Cabotegravir (LA)",
      "therapy_area": "HIV / Infectious Diseases",
      "phase": "Phase 3",
      "status": "Ongoing",
      "start_date": "2022-09-09",
      "estimated_completion_date": "2026-03-20",
      "study_type": "Interventional",
      "sample_size": 5200,
      "countries": ["South Africa", "Kenya", "USA", "Brazil"],
      "sponsor": {
        "name": "ViiV Healthcare",
        "type": "Industry"
      },
      "collaborators": ["NIH", "Bill & Melinda Gates Foundation"],
      "indication_specifics": {
        "primary_endpoint": "HIV incidence vs standard prophylaxis",
        "delivery_route": "Long-acting Intramuscular"
      },
      "competitive_density_score_10": 4,
      "risk_of_late_stage_competitor": "Low",
      "opportunity_relevance_score_10": 8,
      "notes": "Low competition + long-acting modality = strong lifecycle opportunity."
    },

    {
      "trial_id": "CT-2025-004",
      "title": "Pediatric Study of Umeclidinium/Vilanterol for Moderate COPD",
      "molecule": "Umeclidinium/Vilanterol",
      "therapy_area": "Respiratory / COPD",
      "phase": "Phase 2",
      "status": "Recruiting",
      "start_date": "2024-01-22",
      "estimated_completion_date": "2027-08-30",
      "study_type": "Interventional",
      "sample_size": 450,
      "countries": ["India", "Australia", "UK"],
      "sponsor": {
        "name": "GSK",
        "type": "Industry"
      },
      "collaborators": ["All India Institute of Medical Sciences"],
      "indication_specifics": {
        "age_group": "12–17 years",
        "primary_endpoint": "FEV1 improvement at 12 weeks"
      },
      "competitive_density_score_10": 3,
      "risk_of_late_stage_competitor": "Low",
      "opportunity_relevance_score_10": 9,
      "notes": "Pediatric trials create a strong life-cycle moat (paediatric exclusivity)."
    },

    {
      "trial_id": "CT-2025-005",
      "title": "Aripiprazole Monthly Depot vs Weekly Depot: Real-World Adherence Study",
      "molecule": "Aripiprazole (Depot)",
      "therapy_area": "CNS / Schizophrenia",
      "phase": "Phase 4 (Post-market)",
      "status": "Enrolling by invitation",
      "start_date": "2023-02-01",
      "estimated_completion_date": "2025-12-31",
      "study_type": "Observational",
      "sample_size": 1800,
      "countries": ["USA", "Germany"],
      "sponsor": {
        "name": "Otsuka",
        "type": "Industry"
      },
      "collaborators": ["Harvard School of Public Health"],
      "indication_specifics": {
        "primary_endpoint": "Monthly adherence score",
        "secondary_endpoints": ["Hospitalization", "Symptom relapse"]
      },
      "competitive_density_score_10": 5,
      "risk_of_late_stage_competitor": "Medium",
      "opportunity_relevance_score_10": 8,
      "notes": "Depot adherence data useful for lifecycle & repurposing strategy."
    },

    {
      "trial_id": "CT-2025-006",
      "title": "Dapagliflozin Added to Standard CKD Therapy for Stage 3 Renal Patients",
      "molecule": "Dapagliflozin",
      "therapy_area": "Diabetes / Renal",
      "phase": "Phase 3",
      "status": "Completed",
      "start_date": "2021-05-10",
      "completion_date": "2024-12-01",
      "study_type": "Interventional",
      "sample_size": 2100,
      "countries": ["USA", "Germany", "Japan"],
      "sponsor": {
        "name": "AstraZeneca",
        "type": "Industry"
      },
      "collaborators": ["Karolinska Institute"],
      "results_summary": {
        "primary_outcome": "Reduced eGFR decline by 22%",
        "safety_outcome": "No unexpected safety signals"
      },
      "competitive_density_score_10": 8,
      "risk_of_late_stage_competitor": "High",
      "opportunity_relevance_score_10": 7,
      "notes": "Repurposing/label expansion valuable for lifecycle management."
    },

    {
      "trial_id": "CT-2025-007",
      "title": "Pantoprazole 40 mg Rapid-Dissolve Oral Thin Film in GERD",
      "molecule": "Pantoprazole",
      "therapy_area": "Gastroenterology",
      "phase": "Phase 1/2",
      "status": "Recruiting",
      "start_date": "2024-06-15",
      "estimated_completion_date": "2026-03-11",
      "study_type": "Interventional",
      "sample_size": 120,
      "countries": ["India"],
      "sponsor": {
        "name": "Indian Pharma Innovations Ltd.",
        "type": "Industry"
      },
      "intervention_type": "Novel formulation",
      "indication_specifics": {
        "primary_endpoint": "Tmax and Cmax comparison vs tablet",
        "secondary_endpoints": ["Onset of relief"]
      },
      "competitive_density_score_10": 2,
      "risk_of_late_stage_competitor": "Low",
      "opportunity_relevance_score_10": 8,
      "notes": "Good for lifecycle extension through differentiated formulation."
    },

    {
      "trial_id": "CT-2025-008",
      "title": "Azithromycin 100 mg Pediatric Suspension: Stability & Efficacy Study",
      "molecule": "Azithromycin",
      "therapy_area": "Infectious Diseases",
      "phase": "Phase 4",
      "status": "Ongoing",
      "start_date": "2024-01-05",
      "estimated_completion_date": "2026-08-18",
      "study_type": "Interventional",
      "sample_size": 900,
      "countries": ["Nigeria", "Kenya", "India"],
      "sponsor": {
        "name": "WHO",
        "type": "Non-profit"
      },
      "collaborators": ["Unicef", "Kenya Medical Research Institute"],
      "indication_specifics": {
        "primary_endpoint": "Clinical cure rate",
        "secondary": ["Shelf-stability in 40°C environments"]
      },
      "competitive_density_score_10": 3,
      "risk_of_late_stage_competitor": "Low",
      "opportunity_relevance_score_10": 7,
      "notes": "Useful for emerging market formulation optimization strategy."
    }
  ],

  "summary_insights": {
    "highest_competition_trials": ["Semaglutide (Obesity)", "Dapagliflozin (CKD)"],
    "best_low_competition_opportunities": ["Pantoprazole thin-film", "Umeclidinium/Vilanterol Pediatrics"],
    "fastest_growing_areas": ["Obesity", "Oncology combinations", "Long-acting injectables"],
    "low-innovation spaces": ["Older antibiotics"],
    "emerging_market_relevance": ["Azithromycin pediatric", "Cabotegravir LA"]
  }
}
